Inhibition of Nipah Virus by Defective Interfering Particles. (28th February 2020)

• Record Type: Journal Article
• Authors: Welch, Stephen R; Tilston, Natasha L; Lo, Michael K; Whitmer, Shannon L M; Harmon, Jessica R; Scholte, Florine E M; Spengler, Jessica R; Duprex, W Paul; Nichol, Stuart T; Spiropoulou, Christina F
• Is Part Of: Journal of infectious diseases. Volume 221(2020)Supplement 4
• Page Start: S460
• Page End: S470
• Publication Date: 2020-02-28
• Subjects: Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiz564
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: The error-prone nature of RNA-dependent RNA polymerases drives the diversity of RNA virus populations. Arising within this diversity is a subset of defective viral genomes that retain replication competency, termed defective interfering (DI) genomes. These defects are caused by aberrant viral polymerase reinitiation on the same viral RNA template (deletion DI species) or the nascent RNA strand (copyback DI species). DI genomes have previously been shown to alter the dynamics of a viral population by interfering with normal virus replication and/or by stimulating the innate immune response. In this study, we investigated the ability of artificially produced DI genomes to inhibit Nipah virus (NiV), a highly pathogenic biosafety level 4 paramyxovirus. High multiplicity of infection passaging of both NiV clinical isolates and recombinant NiV in Vero cells generated an extensive DI population from which individual DIs were identified using next-generation sequencing techniques. Assays were established to generate and purify both naturally occurring and in silico-designed DIs as fully encapsidated, infectious virus-like particles termed defective interfering particles (DIPs). We demonstrate that several of these NiV DIP candidates reduced NiV titers by up to 4 logs in vitro. These data represent a proof-of-principle that a therapeutic application of DIPs to combat NiV infections may be an alternative source of antiviral control for this disease.